USPTO serial 79330538
BERGENBIO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 1, 2023
- Examiner
- BARRETT, LEAH N
- Law office
- TMEG LAW OFFICE 106
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BERGENBIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James M. Theo
James M. Theo Dinsmore & Shohl LLP222 W. Adams StreetSuite 3400Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations, chemical compounds, biochemical preparations and biologic compounds for scientific or industrial purposes, or for use in laboratories or in research; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for analytical and diagnostic purposes in laboratory use; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for the experimental production of drugs, pharmaceutical products and biotechnological preparations; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for use in the development and manufacture of drugs and pharmaceutical products, namely, drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; active chemical and biochemical ingredients and components for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for scientific or industrial purposes, or for use in laboratories or in research; antibodies, small molecules and proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for use in the development and manufacture of drugs and pharmaceutical products, namely, drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for scientific or industrial purposes, or for use in laboratories or in research; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of drugs and pharmaceutical products, namely, drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; proteins for use in kinase inhibiting technology, for scientific purposes | ACTIVE | — |
| 005 | Drugs and pharmaceutical products for medical purposes, namely, medications for the treatment of cancer and severe respiratory infections; drugs and pharmaceutical products for medical purposes incorporating antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors, or selective inhibitors of cell surface proteins, namely, medications for the treatment of cancer and severe respiratory infections; drugs and pharmaceutical products for medical purposes, for use in oncology and for the treatment of cancers, lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for medical purposes; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for medical laboratory analysis; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease testing, namely, the testing for lung cancer, leukaemia, aggressive cancers, immune evasive cancers, metastatic cancers and severe respiratory infections; antibodies, small molecules and proteins for medical purposes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for medical purposes; protein synthesis inhibitors for medical purposes | ACTIVE | — |
| 042 | Drug discovery and pharmaceutical drug development services; scientific research services; research and development services in the fields of oncology and immunology; scientific research services related to the role of axl and related kinase signalling in disease; scientific research services related to axl biology and its role in mediating aggressive disease; scientific research services related to biomarker discovery; scientific research services related to the development of diagnostic products and services, in the field of treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; scientific research services related to improving the efficacy of chemotherapy, targeted cancer therapy and immunooncology drugs; research and development services in the field of antibodies, small molecules and proteins; conducting and providing research and development services for others in the field of antibody and small molecule technology; medical and biotechnology research services; research, development and engineering of antibodies, small molecules and proteins, namely, anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; laboratory research services relating to the production of antibodies, small molecules and proteins, namely, anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; researching and developing the use of antibodies, small molecules and proteins for the treatment of patients; information, consultancy and advisory services related to the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BerGenBio ASA
- Other trademarks owned by BerGenBio ASA
- Other trademarks owned by BerGenBio ASA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named BERGENBIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 21, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 1, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 1, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 1, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 1, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 1, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 26, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 7, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 7, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 17, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 16, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 16, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 26, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 26, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 26, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 10, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 5, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 5, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 5, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 28, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 28, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 28, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 28, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 28, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 28, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 28, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 28, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 5, 2023 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 26, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 26, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 26, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 24, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 4, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 4, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 18, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 17, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 11, 2022 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Oct 11, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 11, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 11, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 11, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 11, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 9, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 8, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 1, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| May 17, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 17, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 17, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 17, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 17, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 5, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 11, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 7, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 6, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |